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Radiation Qualities
Sebastian Diegeler and Christine E. Hellweg*
Division of Radiation Biology, Institute of Aerospace Medicine, German Aerospace Center (DLR), Köln, Germany
Ionizing radiation can affect the immune system in many ways. Depending on the 
situation, the whole body or parts of the body can be acutely or chronically exposed to 
different radiation qualities. In tumor radiotherapy, a fractionated exposure of the tumor 
(and surrounding tissues) is applied to kill the tumor cells. Currently, mostly photons, and 
also electrons, neutrons, protons, and heavier particles such as carbon ions, are used 
in radiotherapy. Tumor elimination can be supported by an effective immune response. 
In recent years, much progress has been achieved in the understanding of basic inter-
actions between the irradiated tumor and the immune system. Here, direct and indirect 
effects of radiation on immune cells have to be considered. Lymphocytes for example 
are known to be highly radiosensitive. One important factor in indirect interactions is 
the radiation-induced bystander effect which can be initiated in unexposed cells by 
expression of cytokines of the irradiated cells and by direct exchange of molecules via 
gap junctions. In this review, we summarize the current knowledge about the indirect 
effects observed after exposure to different radiation qualities. The different immune cell 
populations important for the tumor immune response are natural killer cells, dendritic 
cells, and CD8+ cytotoxic T-cells. In vitro and in vivo studies have revealed the modu-
lation of their functions due to ionizing radiation exposure of tumor cells. After radiation 
exposure, cytokines are produced by exposed tumor and immune cells and a mod-
ulated expression profile has also been observed in bystander immune cells. Release 
of damage-associated molecular patterns by irradiated tumor cells is another factor in 
immune activation. In conclusion, both immune-activating and -suppressing effects can 
occur. Enhancing or inhibiting these effects, respectively, could contribute to modified 
tumor cell killing after radiotherapy.
Keywords: radiation-induced bystander effects, natural killer cells, cytotoxic T-cells, cytokines, radiotherapy
iNTRODUCTiON
In the response to radiation exposure, interactions with the immune system play an important role 
at multiple levels. Different exposure conditions [e.g., partial body/total body, dose and dose rate, 
fractionation, acute or chronic, radiation quality as determined by linear energy transfer (LET)] are 
expected to modulate the immune system in many ways. A concept of the complex involvement of 
FigURe 1 | Role of immune responses and affection of the immune system in different dose ranges after whole-body exposure (or bone marrow exposure) or partial 
body exposure. A modulation of immune responses can be expected in all dose ranges. Anti-inflammatory effects are observed in low-dose radiotherapy (partial 
body exposure), and proinflammatory and immune stimulating effects in some tumor radiotherapy settings (partial body exposure), but also immune-suppressing 
effects might occur. In whole-body exposure to medium to high doses of ionizing radiation, exacerbation of innate immune responses, and bone marrow depression 
dominate the picture of acute radiation sickness.
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the immune system in the organismal response to whole-body or 
partial body irradiation is suggested in Figure 1.
First of all, immune cells and their lymphoid and myeloid pre-
cursors and stem cells can be affected directly. These effects are of 
major importance for acute medium- to high-dose exposures to ion-
izing radiation as the hematopoietic system. Self-renewing hemat-
opoietic stem cells (HSCs) and more differentiated hematopoietic 
progenitor cells (HPCs) in the bone marrow are extremely radio-
sensitive (1) because of their rapid turnover. Also, some 
of the mature cells from the different lineages such as lymphocytes 
are sensitive to ionizing radiation. Depletion of already differenti-
ated cells by cell death mechanisms and failing replacement by 
stem cells due to cell death [apoptosis of HPCs and HSCs (2)] 
or increased p21Cip1/Waf1 (Gene name: Cdkn1a, cyclin dependent 
kinase inhibitor 1 A) expression leading to a cell cycle block and 
loss of clonogenic function (2) severely affects the immune sys-
tem. Only cells overcoming the cell cycle block are able to replace 
radiation-damaged tissue to regain normal function.
Therefore, immunodepression is a predominant feature of 
acute radiation sickness (bone marrow or hematopoietic syn-
drome) and it appears after whole-body exposure to doses of 
0.5–4 Gy (Figure 1) (3, 4). In the bone marrow syndrome, pro-
gressive lymphopenia develops during the first days after radia-
tion exposure. Exposure to ~2 Gy results in maximal depression 
of the lymphocytes in the blood (5). The lymphocyte deprivation 
decreases the resistance to infections. A possible early granulo-
cytosis is followed by a progressive granulocytopenia (6). Death 
usually occurs from sepsis at 30–60 days after radiation exposure, 
if the patient cannot be carried through the critical period of the 
possibly reversible aplastic state of the bone marrow (5). Long-
term persisting damage (up to 16  months in mice) of HSCs is 
observed after a single acute high-dose exposure (7). Cytological 
abnormalities (multipolar mitosis, micronuclei, mitotic bridges, 
and binucleated cells) and a reduced mitotic index were observed 
Abbreviations: APCs, antigen-presenting cells; CCL, C–C motif chemokine 
ligand; CCR, C–C chemokine receptor type; CD, cluster of differentiation; Cdkn1a, 
cyclin dependent kinase inhibitor 1A; CEA, carcinoembryonic antigen; CHX, 
cycloheximide; CSF-1, colony stimulating factor-1/M-CSF, macrophage CSF/G-
CSF, granulocyte CSF/GM-CSF, granulocyte-macrophage CSF; CTL, cytotoxic 
T-cell; CTLA4, cytotoxic T-lymphocyte associated protein 4; CXCL, C–X–C 
motif chemokine ligand; CXCR, C–X–C chemokine receptor type; DAMPs, 
damage-associated molecular patterns; DCs, dendritic cells; Flt3-L, Fms-related 
tyrosine kinase-3 ligand; HLA, human leukocyte antigen; HMGB1, high mobility 
group box 1; HPC, hematopoietic progenitor cell; HSC, hematopoietic stem cell; 
ICAM-1, intercellular adhesion molecule 1; IFN-γ, interferon γ; IL, interleukin; 
IP-10 (CXCL10), IFN γ-induced protein 10; LET, linear energy transfer; MCP-1 
(CCL2), monocyte chemotactic protein 1; MeV/n, Megaelectronvolt per nucleon; 
MHC-I and II, major histocompatibility complex class 1 and 2; MIC, MHC class 
I chain-related protein; MIP-1β (CCL3), macrophage inflammatory protein 1β; 
MUC-1, mucin-1; NK, natural killer; NF-κB, nuclear factor κB; NKG2D, Natural 
Killer Group 2D; PGE2, prostaglandin E2; PRRs, pattern recognition receptors; 
RIBEs, radiation-induced bystander effects; RNS, reactive nitrogen species; ROS, 
reactive oxygen species; TGF-β, transforming growth factor β; Th, T helper; TLR, 
toll-like receptor; TNF-α, tumor necrosis factor α; Tregs, regulatory T-cells; ULBP, 
UL16-binding proteins; VEGF, vascular endothelial growth factor.
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in human bone marrow cells (e.g., erythroblasts) during the first 
days after accidental sublethal whole-body γ-radiation exposure, 
and they persist at a lower frequency for years after the accident 
(8). The long-term bone marrow injury after acute exposure to 
moderate of high doses of low-LET-irradiation might be caused 
by HSC senescence (9) as indicated by increased p16Ink4a expres-
sion and senescence-associated-β-galactosidase activity (2). 
Radiation qualities with higher biological effectiveness such as 
accelerated iron ions, exhibiting a different LET depending on 
charge and energy of the ion, were shown to initiate long-term 
damage to hematopoietic early and late multipotent progenitor 
cells in mice and reprogramming to a primitive pluripotent state 
(1). Furthermore, chronic low-dose exposure to ionizing radia-
tion might damage bone marrow cells as the hematopoietic niche 
is regarded to be highly sensitive to low-dose ionizing radiation 
exposure (Figure 1) (1).
In addition to the well-known immunosuppression as the 
predominant feature of the bone marrow syndrome, recent studies 
suggest that in the acute radiation syndrome, exacerbated innate 
immune responses play a major role in pathogenesis (10–12). 
Epithelial and endothelial cells are suggested as source of the pro-
inflammatory cytokines in the acute radiation syndrome (12). In 
this complex chain of events, endothelial cells and parenchymal 
cells are damaged (13), endothelial cells and leukocytes are acti-
vated, proinflammatory cytokines such as interleukin-8 (IL-8), 
IL-6, IL-12 and IL-18, prostaglandin E2 (PGE2) and reactive 
oxygen species (ROS) are produced (10, 14), and neuropeptides 
are released (15). Activation of the innate immune system was 
suggested to be involved in target organ damage and adverse 
metabolic and hemodynamic responses (10). In the brain, over-
expression of cytokines such as tumor necrosis factor α (TNF-α), 
IL-1α, and IL-1β occurs within several hours after whole-body 
irradiation of mice (10).
Partial body irradiation is applied in tumor radiotherapy 
or can occur in radiation accidents. Short-term side effects of 
conventional radiotherapy depend on the location, the total 
dose of radiation treatment, the individual radiosensitivity, and 
the size of the radiation field. A persistent accumulation and 
activation of immune cells (e.g., macrophages), resulting in the 
release of proinflammatory cytokines (IL-1, IL-6), contributes 
to radiotherapy-induced side effects (10) such as cutaneous 
radiation syndrome, oral mucositis, radiation pneumonitis 
or esophagitis, or cystitis (16–18). Furthermore, the cytokine 
transforming growth factor β (TGF-β) might be activated in 
the extracellular space and upregulation of its receptors might 
deregulate fibroblast proliferation and differentiation and con-
tribute to radiation-induced fibrosis (19).
Accelerated ion species, especially protons and carbon ions, 
are already established features of state-of-the-art radiotherapy. 
One of their main physical properties is a distance-controlled 
energy distribution (Bragg Peak), resulting in highly localized 
energy deposition of radiation with high LET within a tumor 
while at the same time protecting out-of-field tissue from expo-
sure due to low entry- and even less exit-energies. Such level of 
radiation control makes this therapeutic approach especially suit-
able for treatment in unfavorable locations and strongly promotes 
personalized therapy.
The direct effects of ionizing radiation exposure on different 
immune cells and their stem cells and especially their radiation 
sensitivity were recently summarized in three reviews (20–22), 
therefore, the readers are referred to these reviews and other 
reviews for a detailed description of the immune cells, an overview 
of their function and the direct radiation effects. Shortly, granu-
locytes (eosinophils, basophils, neutrophils), natural killer (NK) 
cells and mast cells are the major players in the innate immune sys-
tem. T-lymphocytes with their subtypes [cytotoxic T-cells (CTLs), 
helper T-cells (Ths) with the subpopulations Th1, Th2, Th17, 
regulatory T-cells (Tregs), memory T-cells] and B-lymphocytes 
(23) [plasma cells, and memory B cells] represent the adaptive 
arm of the immune system. T-lymphocytes are the key players 
in the cell-mediated immune response, while B-lymphocytes 
mediate the humoral reactions. The circulating peripheral blood 
lymphocytes represent only <2% of the lymphocytes in lym-
phoid tissues (24). At the interface of the innate and the adaptive 
immune system, macrophages derived from monocytes and 
dendritic cells (DCs) act as antigen-presenting cells (APCs). 
NKT  cells show features of NK  cells and T-lymphocytes. The 
direct effects encompass reduced survival, proliferation, cell 
cycle alterations, diminished function, gene expression changes 
(25–27), chromosomal aberrations, mutations, and possible 
transformation (28). In vivo, mitotic catastrophe is usually fol-
lowed by necrosis resulting in an inflammatory reaction (29, 30). 
Mitotic catastrophe contributes strongly to the death of tumor 
cells induced by ionizing radiation (29), and is now assumed 
to be the major cell death pathway in solid tumors following 
radiotherapy (31). In tumor radiotherapy, this might result in 
enhanced tumor cell killing by cytotoxic immune cells and also 
in damage to the normal tissue (32).
More subtle changes are expected at low doses, and the 
bystander effect as a non-targeted effect being expressed in unex-
posed cells which are in the vicinity of irradiated cells, becomes 
apparent when only a small fraction of cells was hit. Such 
bystander effects are also relevant in radiotherapy dose ranges, as 
immune cells can enter the irradiated tumor tissue and interact 
with the irradiated tumor cells. They are of high importance for 
cancer immunotherapy concepts in combination with radio-
therapy in which unirradiated immune cells are to be injected in 
the tumor/the patient. Also, the effects on immune cells in their 
niche—mesenchymal stem cells (33, 34) and endothelial cells 
(35) are in the focus of current research activities. Furthermore, 
abscopal effects, which are observed in non-irradiated fields after 
localized radiation exposure, have been recognized for decades, 
most particularly after radiotherapy (12).
In this review, we discuss the intercellular communication in 
the tumor immune response with a focus on different ionizing 
radiation qualities. This encompasses the recruitment of immune 
cells to the irradiation site by, e.g., chemokines, and the functional 
modulation of immune cells.
RADiATiON-iNDUCeD BYSTANDeR 
eFFeCTS
Ionizing radiation, whether it is photonic radiation like X-rays 
and γ-rays or accelerated high energy particles, affects not only 
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the cells they are exposed to. Radiation-induced bystander effects 
(RIBEs) are a response of cells that are not directly hit by ionizing 
photons or traversed by heavy ion species that is initiated by cells 
which received doses of ionizing radiation (36).
After an ionizing radiation event damages a cell, pathways 
leading to the repair of the damages or the induction of apoptosis 
also induce the production of factors that can travel outside of 
the cell or from cell to cell, either by secretion or via cell-to-cell 
connecting channels. These factors act as damaging agents or 
signaling molecules and can affect other cells in a paracrine or 
endocrine manner.
Radiation-induced bystander effects have been first described 
by Nagasawa and Little in an experiment, where only a small 
fraction of the cells (<1%) were traversed by an α-particle, but 
more than 30% of the whole cell population showed damages 
(37). At present time, damages by RIBE are characterized as 
DNA damage, chromosome aberrations, sister-chromatid 
exchanges, genomic instability, and cellular senescence. Among 
the  damaging agents are ROS and reactive nitrogen species 
(RNS) (38, 39).
Radiation-induced bystander effects are not only an indirect 
way for ionizing radiation to cause destruction. The secretion 
of signaling factors of this particular cellular response can also 
protect cells from further damages by preenhancing repair 
mechanisms or lead to a faster clean-up of radiation-damaged 
cells (40–42).
The most prominent signaling molecules in RIBE are factors 
triggering an immune response. Part of the damage response 
of an irradiated cell is the activation of the transcription factor 
nuclear factor κB (NF-κB) (43). Downstream of NF-κB activation, 
chemokines and cytokines are produced and secreted, which can 
attract and stimulate cells of the immune system.
Besides cytokine and chemokine secretion, cells can 
communicate via extracellular vesicles or exosomes. These 
membrane-coated bodies can contain a multitude of factors 
ranging from proteins to micro-RNA that can modulate cel-
lular functions and induce signaling pathways. After secretion 
of the vesicles into the extracellular space, exosomes can affect 
neighboring cells by binding to surface receptors or by uptake 
and intracellular release of their content. Exosomes in RIBE 
have been associated with DNA damage, survival, proliferation, 
and signal transduction, resulting from the variety of factors 
carried within and the possible ways to impact recipient cells 
(44–52). The influence of ionizing radiation on composition 
and secretion of exosomes was recently reviewed by Jelonek 
et al. (49).
In the innate immune response, recognition of pathogen-
associated molecular patterns or damage-associated molecular 
patterns (DAMPs) by germline-coded cell surface or intracellular 
receptors [pattern recognition receptors (PRRs)] is the central 
trigger of activation. In the adaptive immune response, antigen 
presentation by APCs to T- and B-lymphocytes is the central 
 process for their activation. Antigens are bound to major 
 histocompatibility complex class I (MHC-I) molecules on the 
surface of body cells and to MHC class II (MHC-II) molecules 
on APCs [in humans: MHC class Ia – human leukocyte antigen 
(HLA)-A, -B and -C; MHC class Ib  –  HLA-E, -F-, -G; MHC 
class II  – HLA-DM, -DO, -DP, -DQ, -DR]. Antigen recogni-
tion by T  helper cells and B-cells or CTL in combination with 
co-stimulation, intercellular adhesion and stimulation by cytokines 
results in their activation. Therefore, radiation induced modifica-
tions of these intercellular communication pathways are of utmost 
importance in the non-targeted response of the immune system.
Radiation-induced bystander effects in the immune system 
encompass a complex network of signaling pathways, ranging 
from the DNA damage response of irradiated cells and unirradi-
ated cells over the regulation of surface molecules on stationary 
body cells as well as circulating immune cells after radiation 
exposure and on the non-irradiated neighbors to the response of 
immune cells, due to direct or indirect intercellular communica-
tions of immune cell populations.
In vitro experiments for analysis of RIBE are based on transfer 
of conditioned medium from irradiated cells on unirradiated 
cells, coculture of irradiated and unirradiated cells, or irradiation 
of a subpopulation of cells by means of a microbeam or partial 
shielding.
ACTiON OF iMMUNe CeLLS AFTeR 
TUMOR iRRADiATiON
Tumors contain diverse immune cells, and therefore, the responses 
of immune cells to irradiated tumor cells including RIBE are an 
important factor for the overall outcome of the tumor therapy. 
Noteworthy for this topic is the strict differentiation of in vitro 
and in  vivo studies: in  vitro experiments with unirradiated 
immune cells can show an uncompromised immune response 
against irradiated tumor cells. In in vivo studies, immune cells 
may also be irradiated during radiation therapy of the experi-
mental tumor.
The responses of immune cells to stresses of any kind differ 
as much as their population diversity. While there are actively 
lytic cell populations, such as CD8+ CTLs and NK cells, there 
is also a host of immune actions that are necessary for initiating 
aforementioned lytic responses (e.g., dendritic, monocytic, and 
macrophage-mediated presentation of antigens) and enhancing 
actions (Th1 and Th2 responses). Opposed to those proinflam-
matory lymphocytes are cell populations that suppress the 
responses, for example, Tregs that secrete the hematopoietic 
cell activity regulating and anti-inflammatory TGF-β and the 
immune-suppressing IL-10 (53).
Activation of CTLs
Involvement of cytotoxic immune cells has been studied in a 
variety of model systems with different radiation qualities. The 
most notable modifications of lymphocyte actions are summa-
rized in Table 1. Activation of CTL (shown in Figure 2) is mainly 
triggered via the T-cell receptor. In 67NR and A20 tumor-bearing 
mice irradiated with γ-rays (2–6 Gy), increased CTL cytotoxicity 
was reported (54). In an in vitro study by Garnett et al. (55) using 
several carcinoma cell lines, it was shown that after irradiation 
with γ-rays (10–20  Gy), WiDr, Caco-2, SW620, SW1463, and 
HCT116 cells were more sensitive to CTL-mediated lysis primed 
against carcinoembryonic antigen (CEA), while A549 cells 
TABLe 1 | Modulation of lymphocyte activity after irradiation of tumor tissue.
Tumor cell Radiation quality Dose Study 
type
Lymphocyte 
type
Activity Reference
Mouse adenocarcinoma γ-Irradiation (137Cs source) 20 Gy In vivo CTL ⇑ (56)
67NR (breast) γ-Irradiation (60Co source) 2–6 Gy In vivo CTL ⇑ (54)
A20 (lymphoma)
WiDr (colon) γ-Irradiation (137Cs source) 10–20 Gy In vitro CTL ⇑ (55)
Caco-2 (colon)
SW620 (colon)
SW1463 (colon)
HCT116 (colon)
A549
MelJuSo (melanoma) γ-Irradiation (137Cs source) 1–30 Gy In vitro CTL ⇑ (59)
RMA-S lymphoma Radiation therapy (presumed X-rays) a In vivo NK ⇑ (60)
B16 melanoma
A549 (lung carcinoma) X-rays exposure (ClinaciX Linear Accelerator) 8 Gy In vitro NK ⇑ (61)
NCI-H23 (lung adenocarcinoma)
MDA-MB-231 (breast) Electron beam exposure (Elekta Synergy linear 
accelerator)
8 Gy In vivo NK ⇑ (62)
U87MG (glioblastoma)
A673 (muscle)
PANC-1 (pancreas)
Lewis Lung carcinoma X-rays exposure (6-MV photon beam, dose rate  
6.1 Gy/min)
12 Gy In vivo Treg ⇑ (63)
CT-26 colon carcinoma
B16 melanoma γ-Irradiation (137Cs source) 6–12 Gy In vivo Treg ⇑ (64)
EL-4 lymphoma
PANC-02 (pancreas) γ-Irradiation (Siemens Gammatron) 5 Gy × 2 Gy In vivo CTL, NK CTL > NK (65)
LNCaP (prostate) γ-Irradiation (137Cs source) 8 Gy In vivo CTL ⇑ (66)
MDA-MB-231 (breast)
H1703 (lung) Proton ion irradiation (200 MeV, LET 0.5 keV/µm) 8 Gy
JHC7 (chordoma)
Mouse SCCVII (squamous cell carcinoma) Carbon ion irradiation (290 MeV/n, LET 77 keV/µm) 10 Gy/minb In vivo CTL+ DC ⇑ (67)
⇑ up.
aDose not indicated.
bDuration of irradiation not indicated.
LET, linear energy transfer.
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responded to Fas-mediated cell lysis. Increased expression of 
Fas (CD95) was also observed on tumor cells in a MC38 mouse 
adenocarcinoma cell model after γ-irradiation (20  Gy), which 
enhanced the lytic activity of CTL (56). Expression of the surface 
proteins Fas, CEA, intercellular adhesion molecule 1 (ICAM-1), 
mucin-1 (MUC-1), and MHC-1 was increased in those cell lines 
as well, enhancing their susceptibility to immune mediated lysis 
(55). ICAM-1 can engage in receptor-ligand binding between a 
T-cell and an antigen-presenting DC and thereby contribute to 
T-cell activation (21) as well as recruitment of immune cells from 
the blood stream to endothelial cells before extravasation to the 
tumor (57, 58).
Similar results were obtained using 200  MeV protons (pro-
duced using a passive scattering proton beam). In in vitro tumor 
cell models (human prostate (LNCaP), breast (MDA-MB-231), 
lung (H1703) carcinoma, and chordoma (JHC7) cells), expres-
sion of HLA-ABC, CEA, MUC-1, and ICAM-1 was increased 
after proton (8  Gy) and γ-irradiation (8  Gy), as well as sensi-
tivity of the tumor cells to CEA-specific CTL-mediated lysis 
increased (66). Increased CTL activity has been partially allotted 
to the production of unique MHC-I antigenic peptides after 
γ-irradiation (1–25 Gy) leading to increased tumor recognition 
by T-cells (59).
In vivo studies with carbon ion irradiation (290  MeV/n, 
LET 77 keV/µm) of tumor-bearing mice revealed an increased 
CTL-associated lysis of isolated tumor splenocytes after carbon 
ion irradiation treatment with supplementary intratumoral DC 
injection (67).
Activation of NK Cells
The Natural Killer Group 2D [NKG2D, reviewed by Spear 
et al. (68)] receptor promotes amongst others the activation of 
NK  cells. The human NKG2D receptor recognizes the ligands 
MHC class I chain-related protein A (MIC-A) and B (MIC-B) 
and HCMV UL16-binding proteins [ULBP1-6 (68)]. Expression 
of NKG2D ligands has been found to be increased in irradiated 
tumor cell lines [NCI-H23, A549 (61, 69)] resulting in enhanced 
activity of NK cells (summarized in Figure 3) toward tumor cells 
after X-irradiation (8 Gy). The response was presumed to be trig-
gered by an upregulation of the NKG2D ligands MIC-A/B and 
FigURe 2 | Activation of CD8+ cytotoxic T-cells (CTL) by tumor specific antigens presented by the irradiated tumor cell and dendritic cells (DCs). After irradiation, 
the tumor cell shows an increased expression of surface markers CD95 (Fas), carcinoembryonic antigen (CEA), intercellular adhesion molecule 1 (ICAM-1), and 
mucin-1 (MUC-1), as well as upregulated expression of major histocompatibility complex class I (MHC-I; HLA-ABC, human leukocyte antigen A, B, and C). While 
increased expression of CEA, ICAM-1, and MUC-1 are found to enhance cytolytic T-cell activity, CD95, and MHC-I are responsible for the activation of the T-cell. 
Increased expression of either has been associated with elevated activation of CTL. By binding with surface bound Fas-ligand (FasL) to the tumors’ CD95, T-cells 
can initiate tumor cell death via apoptosis. MHC-I molecules on the other hand present tumor specific antigens to the T-cell via the T-cell receptor and initiate 
degranulation of tumor necrosis factor α (TNF-α), perforines, and granzymes, thereby lysing the target tumor cell. After irradiation, tumor cells were found to produce 
unique antigen peptides, leading to increased tumor recognition. DCs, in their role as antigen-presenting cells, enable radiation-induced CTL lysis. DC take up tumor 
specific antigens and present them via MHC-II molecules to T-helper cells (CD4+), which prime and activate CTL, e.g., via secretion of interleukin-2 (IL-2).
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ULBP1-3 and could be further increased by inhibition of histone 
deacetylase (61).
Upregulation of MHC-I molecules and heat-shock proteins 
may abolish this activation (Figure 3) by induction of an increased 
expression of inhibitory NK cell surface receptors (61). NK cell 
activity has also been found to be diminished after cleavage of 
NKG2D ligands via matrix metalloproteases (69, 70).
An enhanced radiotherapy effect mediated by NK  cells has 
been reported after electron irradiation (8  Gy). The cytotoxic 
effect of NK  cells was tested on various cancer stem cell lines 
(MDA-MB-231, U87MG, A673, and PANC-1) in  vivo, where 
mice were inoculated with cultured tumor cells and locally irradi-
ated, then injected with NK cells, and in vitro, assessing the NK 
cytotoxicity directly on irradiated tumor cell (62).
As mentioned above, in vivo studies can imply direct irradia-
tion effects on immune cells. A way around this is to inject non-
irradiated lymphocytes into the irradiated tumor-bearing host 
and analyze the effects.
An in vivo study explained a reduced tumor volume (RMA-S 
lymphoma/B16 melanoma) in mice by injected NK  cells after 
5 Gy total body irradiation. The effect was even more pronounced 
after prestimulating the NK cells with IL-12, -15, and -18, with 
highly increased expression of interferon γ (IFN-γ), granzyme B, 
and perforin. Those prestimulated NK cells were found to have 
rapidly proliferated in dependence of IL-2 production by CD4+ 
Th-cells (60).
involvement of DCs
Enhanced antitumor response after X-irradiation (PANTAK 
Therapax DXT 300 Model X-Ray Unit, 42.5  Gy) has been 
linked to DCs. Intratumoral injection of DC was performed in 
 mice bearing irradiated D5 tumors, resulting in reduced tumor 
size and increased IFN-γ secretion (71). As shown by Scholch 
et al. (65), in the in vivo (PANC-02 cells in mouse model) antitu-
mor response of immune cells after irradiation (5 Gy × 2 Gy), the 
CTL mediated response dominates over NK cells, and was shown 
to be abrogated by depletion of DC, indicating a necessity of DC 
mediated antigen presentation for the immune cell effectiveness 
against tumor tissue. Although very promising, the described 
effects do not take the radiation effect on immune cells into 
account, since no immune cells were injected after irradiation 
(65). After X-irradiation (5 Gy × 2 Gy, 3 Gy × 5 Gy, 15 Gy), DC 
show an increased expression of IL-2R (CD25), which can medi-
ate an increased activation of CD4+ T-cells via presentation of 
the activating IL-2 to the T-cell [and potentially CTL and NK cells 
as well, although not tested in the study (72)].
FigURe 3 | Activation and inhibition of natural killer (NK) cells by irradiated tumor cells. (A) Irradiated tumor cells show increased expression of the surface proteins 
MHC class I chain-related protein A and B (MIC-A/B) and HCMV UL16-binding proteins (ULBP1-3), which are ligands for NK cell activating receptors NKG2D. 
Activation of NK cells is orchestrated by a balancing of bound activating and inhibiting receptors. Increased expression of NKG2D ligands therefore shifts the 
balance toward NK cell activation and triggers degranulation of perforine, granzyme B, and interferon γ (IFN-γ)—the NK cells’ mediators of cytolytic activity. (B,C) 
Decreasing NK cell cytotoxicity on the other hand is mediated by different mechanisms. (B) Major histocompatibility complex class I (MHC-I) is a ligand for the 
inhibiting receptors on the NK cell surface and has been found to be elevated in irradiated tumor cells. By increasing the binding of inhibitory receptors, the NK cells’ 
cytotoxic capabilities are diminished. (C) Another mechanism is to decrease the binding to the activating NK cell receptors, like NKG2D. This can be accomplished 
by cleaving the respective ligands on the target cell surface with matrix metalloproteases (MMP).
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involvement of Tregs
On the other hand, immunosuppressive Tregs were found to be 
increased in irradiated tumors in an in vivo mouse study, bear-
ing lung and colon tumors (63) as well as in tumors and tumor 
draining lymph nodes of mice injected with mouse melanoma 
and lymphoma cell lines (64). The increased presence of Tregs 
was associated with increased tumor growth and has been 
hypothesized to depend on Langerhans cells, the DCs in the 
epidermis (64). Systemic inhibition of Tregs using cycloheximide 
(CHX) and anti-CD25 antibodies proved to increase the number 
of CD8+ and CD4+ non-Tregs. Along with those results, CHX 
and anti-CD25-antibody treatment resulted in enhanced tumor 
regression, indicating a suppressive function of Tregs (63). In other 
in vivo studies, Tregs were suppressed by blockage of cytotoxic 
T-lymphocyte associated protein 4 (CTLA4) in mice injected 
with 4T1 mouse mammary carcinoma or CD-26 murine colon 
cancer cells. Subsequent radiation exposure with 10 and 12 Gy 
of γ-irradiation resulted in tumor reduction that was associated 
with CTL-mediated cytotoxicity (73, 74). In the study by Son 
et al., the irradiation treatment was augmented with immature 
DC (74), but due to different irradiation parameters as well as 
different tumor application of the two studies, the effectiveness 
of this augmentation cannot be assessed.
Bystander and Abscopal effects
Monocytes and T-cells were shown in vitro (THP-1 and Jurkat 
cell lines, respectively) to have increased viability after incubating 
them with conditioned medium from carbon ion irradiated neu-
ronal tumor cells (SH-SY5Y and U87; Carbon ions 165 MeV/n, 
LET 30  keV/µm, 1–5  Gy), as well as decreased migration of 
THP-1, hinting at more in-depth interactions of immune cells in 
response to radiation (75).
Radiation therapy with an electron beam (fractionated 8 Gy on 
three consecutive days; Varian Truebeam linear accelerator) has 
been shown to slow tumor growth of mice bearing 67NR tumors 
in  vivo in an abscopal manner (76). In the same model, after 
enrichment of DC using DC growth factor Flt3-L (Fms-related 
tyrosine kinase-3 ligand), abscopal tumor size reduction was 
observed after low doses (2–6 Gy) of γ-irradiation (60Co source). 
The effect was proven to be T-cell dependent, as abscopal tumor 
size was not influenced in T-cell deficient mice (54).
The systemic inhibition of Tregs using CHX and anti-CD25-
antibodies in an in vivo tumor-bearing mouse model (lung and 
colon carcinoma) or via CTLA4 blockage in an in vivo tumor-
bearing mouse model (colon carcinoma) after irradiation of 
the tumor resulted in reduced growth of distant non-irradiated 
tumor cells (63, 74). The indicated suppressive action of Tregs on 
antitumor responses can thereby also be expected non-irradiated 
tumors.
These studies show that irradiation of tumor cells or tissue has 
long-ranging effects on different immune cell subpopulations. 
This results in activation of CTL and NK  cells, supported by 
increased activity of DCs, which meets an orchestrated immune 
suppressive response initiated by Tregs. Activation of CTL and 
NK cells was shown in in vitro and in vivo studies, Treg activation 
only in vivo. As a broad variety of neoplastic cell lines activated 
these immune cell populations, the tumor cell type seems to have 
no apparent influence on immune cell activation.
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CYTOKiNeS AND CHeMOKiNeS
The Tumor Milieu
The presence of immunosuppressing cyto- and chemokines is vital 
to the development and progression of tumor cells. The tumor 
cells themselves can secrete factors that protect them from lysis 
via CTLs or NK cells or elicit cytokine expression in other cells 
that enable tumor survival, most notably are TGF-β and IL-10.
Transforming growth factor β has been shown to reduce a 
wide variety of antitumor immune functions. It inhibits growth of 
immune cells and reduces IL-2, IL-2R, IFN-γ, and NKG2D expres-
sion resulting in impairment of their activity. Furthermore, down-
regulation of MHC-I molecules on the tumor cell surface reduces 
their susceptibility to CTL-mediated tumor cell lysis. Expression of 
TGF-β by several tumor types has been reported (77, 78).
Interleukin 10 is one of the immune system’s “Off-Switches,” 
known for its regulatory characteristics in suppressing 
inflammatory responses (79). It effectively reduces antigen-
presentation, Th1 responses, NK  cell cytokine expression, 
and functions of monocytes and macrophages. An important 
way of inactivating the inflammatory immune response is by 
reducing the abilities of DCs to present antigens and to produce 
proinflammatory cytokines such as IL-12 (80). IL-12 can pro-
mote NK-mediated actions against tumor tissue. Among other 
factors associated with tumor growth are TNF, IL-1, IL-6, IL-8 
[C-X-C motif chemokine ligand 8 (CXCL8)], IL-11, IL-17a, 
IL-22, acute phase proteins, CCL20, PGE2, colony stimulating 
factor-1 (CSF-1)/macrophage CSF (M-CSF), vascular endothe-
lial growth factor (VEGF), and granulocyte-macrophage CSF 
(GM-CSF) (81–86).
The field of cytokines promoting tumor development and 
progression is vast and has been reviewed elsewhere (81–85). The 
communicative relationship of cytokines in radiation biology, as 
well as general notions on their functions, has been extensively 
reviewed by Schaue et al. (87). One can suspect that modulation 
of cytokine expression may be able to accomplish long ranging 
effects in terms of non-targeted responses after irradiation expo-
sure. In this review, the focus lies on the modulation of cytokine 
expression after exposure to ionizing radiation from differing 
radiation qualities and irradiation schemes.
impact of irradiation of Tumor Cells on 
Cytokine expression
Since the tumor environment is of immunosuppressive nature, 
the question arises, how irradiation of tumor cells modulates the 
cytokine responses that induce or further suppress the immune 
response. The cytokine and chemokine response of diverse tumor 
cell lines is shown in Table 2 and Figure 4.
Fractionated irradiation (5 Gy × 2 Gy, 3 Gy × 5 Gy, 15 Gy) of 
human colorectal adenocarcinoma cells (SW480 cell line) with 
X-rays has been reported to increase expression and secretion of 
proinflammatory cytokines IL-6, IL-8, IL-12p70, and TNF-α by 
DCs. The immunosuppressive cytokine IL-10 and the proinflam-
matory cytokine IL-1β were insignificantly increased without 
impeding antitumor response of Th1-cells (72).
The glioblastoma cell line T98G expressed and secreted an 
elevated level of IL-6 and IL-8 after γ-irradiation (1 Gy) (89). In 
addition to IL-6 and IL-8, CXCL1 expression was induced by high 
γ-radiation doses (10–30  Gy) in LN-229 glioma cells, this was 
observed for several days after irradiation (98).
Desai et al. (97) analyzed cytokine expression in the tumor cell 
lines HT1080, U373MG, HT29, A549, and MCF-7, using a single 
dose (2 and 6 Gy) and fractionated doses (2 Gy × 3 Gy) of γ-rays. 
Amongst the cytokines tested were TNF-α, IL-1β, IL-6, TGF-β, 
monocyte chemotactic protein 1 (MCP-1/CCL2), IL-15, VEGF, 
G-CSF, GM-CSF, Flt3-L, and IFN-γ-induced protein 10 (IP-10). 
While some cytokines (TNF-α, IL-8, IL-15, GM-CSF, and TGF-β) 
were highly upregulated after 6 Gy single-dose γ-irradiation, the 
expression profile strongly depended on the dose (TGF-β was 
downregulated in HT1080 cells at 2  Gy, highly upregulated at 
6 Gy, and moderately upregulated in the fractionated irradiation 
scheme), cell line (downregulation of IL-6 in every irradiation 
scheme of U373MG cells but upregulation in HT1080 and A549 
cells) and fractionation (IL-1β was downregulated in HT29 cells 
at 2 and 6  Gy single-dose irradiation but upregulated in the 
fractionated irradiation scheme).
In a mouse tumor model (RipTag-5 transgenic mice), TNF-α, 
IL-12p70, and INF-γ expression was found to be elevated, while 
VEGF and TGF-β were decreased after irradiation with 2  Gy 
γ-rays (100).
Tumor necrosis factor α and IL-1α were also reported to be 
released in H446 lung cancer cells after irradiation with γ-rays 
(8 Gy), but only TNF-α after irradiation with accelerated carbon 
ions (290 MeV/n, LET 13 keV/µm, 2 Gy) (99). IL-1 can act as 
stromal growth factor in tumors (103).
In conclusion, exposure to X-rays or γ-rays in therapeutic 
dose ranges (in fractionated or single-dose regime) modulates the 
expression of cytokines in many different tumor cell lines and also 
spontaneous tumor models.
impact of irradiation of immune Cells on 
Cytokine expression
Monocytes (THP-1 cell line) expressed reduced levels of the 
activating factors IL-15, IL-17, macrophage inflammatory 
protein 1β (MIP-1β, also known as CCL3) and IL-2 as well 
as increased levels of Treg-attracting IP-10 [CXCL10 (104)], 
Rantes (CCL5) and immunosuppressive VEGF (105) 24  h 
after irradiation with 1.5  Gy α-particles (241Am Source, LET 
127 keV/µm) (106). Irradiation of THP-1 derived macrophages 
with 0.5–20 Gy carbon ions (18.3 MeV/n, LET 108 keV/µm) has 
been shown to result in decreased TNF-α and IL-6 expression. 
Only extremely high doses (50 Gy) of carbon ions resulted in 
this study in an increased IL-6 expression (107). Irradiation of 
monocytes and macrophages with α-particles or accelerated 
carbon ions in therapeutic dose ranges (fractionated scheme) 
may therefore negatively modulate the immune response 
against tumor cells.
Release of DAMPs
Damage-associated molecular patterns are secreted or released 
biomolecules that can initiate inflammatory responses upon 
binding to recipient receptors. Among those biomolecules are 
DNA molecules that are recognized by PRR anywhere outside 
the cell nucleus, or damaged RNA, which may be released in 
TABLe 2 | Cyto- and chemokine response and damage-associated molecular patterns (DAMPs) release by tumor cells after irradiation.
Tumor cell Radiation quality Dose Study 
type
Cytokine/chemokine expression Reference
4T1, 67NR, HTB-20 (breast carcinoma) γ-Irradiation (137Cs source) 2–12 Gy In vivo CXCL16 ⇑ (88)
In vitro
T98G (glioblastoma) γ-Irradiation (60Co source) 1 Gy In vitro IL-6, IL-8 ⇑ (89)
4T1, 67NR (breast carcinoma), B16/F10 
(melanoma), MC57 (fibrosarcoma), MCA38  
(colon carcinoma)
γ-Irradiation (137Cs source) 12 Gy In vivo CXCL16 ⇑ (90)
A549, TE2, KYSE70 (esophageal 
squamous), NCI-H460 (large cell 
carcinoma), WiDr (colon adenocarcinoma), 
MCF-7, NCI-H1703 (lung), DU-145, PC-3 
(prostate), HCT-15 (colorectal), SW480, 
T98G and U251MG
Photonic 2.1–15 Gy In vitro HMGB1 ⇑ (91–95)
DF-19, BW-225 (squamous cell carcinoma) Ionizing radiation (not specified) 2 Gy In vitro CXCL1, CXCL12 = (96)
HT1080 (colorectal tumor), U373MG, HT29, 
A549, MCF-7
γ-Irradiation (60Co source) 2 Gy, 6 Gy, 
3 Gy × 2 Gy
In vitro Flt3-L, G-CSF, GM, CSF, IL-1β, 
IL-6, IL-8, IL-15, IP-10, MCP-1, 
TNF-α, TGF-β, VEGF
⇑ (97)
G-CSF, GM-CSF, IL-1β, IL-6, 
IL-8, MCP-1, TNF-α, TGF-β
⇓
SW480 (colorectal) X-rays 5 Gy × 2 Gy, 
3 Gy × 5 Gy, 
15 Gy
In vitro IL-6, IL-8, IL-12p70, TNF-α, 
IL-10, IL-1β
⇑ (72)
LN-229 (glioma) γ-Irradiation (Nordion GC40 
Gammacell irradiator)
10–30 Gy In vitro IL-6 ⇑ (98)
IL-8, CXCL1 (only mRNA)
NCI-H446 (lung) γ-Irradiation (137Cs source) 8 Gy In vitro TNF-α, IL-1α ⇑ (99)
Carbon ions (290 MeV/n,  
LET 13 keV/µm)
2 Gy TNF-α ⇑
RipTag5 mice (spontaneous insulinoma) γ-Irradiation (60Co source) 2 Gy In vivo TNF-α, IL-12p70, IFN-γ ⇑ (100)
VEGF, TGF-β ⇓
MCF7, SKBR3, and MDA-MB231 (breast) γ-Irradiation (137Cs source) 10–20 Gy In vitro CXCL16 ⇑ (101)
NR-S1 and SCCVII (squamous cell 
carcinoma), NFSa, #8520 (fibrosarcoma)
γ-Irradiation (137Cs source) 30–50 Gy In vivo CCL3 (only mRNA) ⇑ (102)
Carbon ions (290 MeV/n,  
LET 50 keV/µm)
30 Gy CCL3, CXCL2 (only mRNA)
TE2, KYSE70, A549, NCI-H460 and WiDr Carbon ions (290 MeV/n,  
LET 30 keV/µm)
0.9–3.5 Gy 
(iso-survival 
dose D10a)
In vitro HMGB1 ⇑ (93)
⇑ up, ⇓ down.
aThe D10 dose represents the radiation dose required to reduce the surviving fraction to 10%.
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response to damages induced by ionizing radiation. Certain 
signaling proteins may also be recognized by PRR and stimulate 
immune functions.
One of those proteins is the high mobility group box 1 (HMGB1), 
a protein that under normal conditions binds to chromosomal 
DNA and facilitates nucleosomal structure maintenance and 
regulates gene expression. Acting as a DAMP (Figure 4), HMGB1 
can support recruitment of immune cells via the chemokine recep-
tor CXCR4 (which is bound by CXCL12) and activate immune 
responses via toll-like receptor 4 (TLR4) or induce caspase-
1-dependent apoptosis (93, 95, 108) as well as DC maturation, Th1 
polarization (109), and IFN-γ release of NK cells (110). It has been 
shown to be released after 2–15 Gy, X- and 0.9–3.5 Gy carbon ion 
irradiation by normal human fibroblasts (GM0639) and human 
bronchial epithelial cells (16HBE), as well as by the tumor cell lines 
A549, TE2, KYSE70, NCI-H460, WiDr, and the mouse melanoma 
cell line B16-F10 (93–95). Similar findings were reported in tumor 
cell lines of various tissue origins (MCF-7, NCI-H1703, DU-145, 
PC-3, HCT-15, SW480, T98G, and U251MG cells) (91, 92). Upon 
TLR9 stimulation, HMGB1 induces expression of IL-12p70, 
IL-12p40, IFN-α, IFN-γ, and TRAIL in DCs (111).
HMGB1 has also been indicated to induce NF-κB activity, as 
measured by p65 translocation as well as IκBα degradation, in 
presence of PRR CD14 and TLR4 (112). HMGB1 also induces 
increased TNF-α expression in human peripheral blood mono-
nuclear cells, as well as TNF-α, IL-1α, IL-1β, IL-1RA, IL-6, IL-8, 
MIP-1α, and MIP-1β in human monocytes, but not IL-10 or 
IL-12 (113).
This indicates that inflammatory protein expression of immune 
cells may be in part due to stimulation via HMGB1 acting as 
DAMP after irradiation injury. As part of the bystander response 
of immune cells, this HMGB1 induced expression of cytokines 
FigURe 4 | Cytokine and chemokine expression by irradiated tumor cells, recruitment of immune cells and cytokine expression of the involved immune cells. Tumor 
cells express a plethora of soluble factors, cytokines and chemokines, and after irradiation, the secretion profile is modified. On the one hand, proinflammatory 
cytokines, like interleukin-6 (IL-6), IL-8, IL-12p70, tumor necrosis factor α (TNF-α), interferon γ (IFN-γ), and IL-1α, are increasingly expressed in tumor cells models 
in vitro and in vivo. On the other hand, the expression of immune-suppressive soluble factors is modified. IL-10 and IL-1β expression is increased, but secretion of 
vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) is reduced. Further, chemokines, like CXCL16, are increasingly expressed and 
initiate recruitment of natural killer (NK) cells and other immune cells. The secretion of the damage-associated molecular pattern molecule high mobility group box 1 
(HMGB1) is elevated as well in irradiated tumor cells, which leads to a activation of immune cells via the toll-like receptor 4 (TLR4), recruitment of immune cells via 
chemokine receptor CXCR4, as well as modification of cytokine expression of peripheral blood mononuclear cells.
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may lead to prompting further immune action such as CD8+ 
T-cell or NK  cell mediated killing of irradiated tumor tissue. 
There is very little data available regarding HMGB1 modulation 
by proton or carbon ion irradiation. This calls for more research in 
this upcoming and promising radiotherapy approach—especially 
in context of DAMP interaction with immune cells. While the 
primary signaling pathways for interactions of HMGB1 with any 
leukocyte population can be elucidated using X-irradiation, the 
effect of particle irradiation on this intercellular communication 
can only be assessed with specifically designed experiments for 
this question.
Bystander Cytokine expression
Besides the cyto- and chemokine expression of irradiated tumor 
or immune cells, bystander cells not directly hit by radiation 
might modify their gene expression profile. In coculture, U937 
macrophages have been shown to secrete TNF-α and IL-1α 
(IL-1α not at high doses) after irradiation of NCI-H446 lung 
cancer cells with γ-rays (137Cs Source, 8  Gy) but only TNF-α 
after irradiation with accelerated carbon ions (290  MeV/n, 
LET 13  keV/µm, 2  Gy) (99). Microbeam irradiation of 0.45% 
of a THP-1 derived   macrophage population with 5  Gy 
carbon ions (18.3  MeV/n,  LET 108  keV/µm) using a heavy 
ion   microbeam  resulted in significantly reduced expression of 
TNF-α and IL-6 (107).
Chemokines and Lymphocyte Recruitment
The release of chemokines by irradiated cells and build-up of a 
chemokine gradient results in recruitment of selected immune 
cell populations to the irradiation site.
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The chemokine CX3CL1 can recruit osteoclasts which are 
formed by fusion and differentiation of monocytes (114). This 
might have clinical relevance for osteolytic tumors.
Expression of CXCL16, the only known ligand for chemokine 
receptor CXCR6—expressed on NK cells, is increased in various 
breast cancer (MCF7, SKBR3, and MDA-MB231, 4T1, 67NR, 
HTB-20), melanoma (B16/F10), fibrosarcoma (MC57), and 
colon carcinoma (MCA38) cell lines after γ-irradiation (2–20 Gy) 
(88, 90, 101). This increased expression of CXCL16 facilitates an 
enhanced migration NK cells (Figure 4) toward the tested tumor 
cells (101).
Macrophage inflammatory protein 1α (CCL3) is a 
T-lymphocyte/monocyte derived chemokine recruiting CCR1/
CCR5 expressing leukocytes (monocytes, DC, NK-, and T-cells). 
Administration of an active CCL3 agent (ECI301) resulted in 
reduction of tumors in vivo (Colon26 adenocarcinoma, MethA 
fibrosarcoma and Lewis lung carcinoma cells in mice) after 
electron irradiation (6 MeV electron beam, 6 Gy). Depletion of 
CD8+ T-cells reduced the antitumor effect of CCL3 administra-
tion indicating radiation induced recruitment of this cell popula-
tion to the tumor site (115).
Abscopal effects
CCL3 administration also served to reduce tumor size of non-
irradiated tumors in the in  vivo model used by Shiraishi et  al. 
(115). This effect was dependent CD4+ Th cells and NK cells, as 
depletion of those cell populations has shown. This indicates a 
CCL3 dependent recruitment of those populations to the non-
irradiated tumor after irradiation (115).
CONCLUSiON
After the initial irradiation of tumor cells, the RIBE can contrib-
ute to a more effective elimination of the tumor by recruiting 
immune cells to the tumor and by activating immune cells at the 
tumor site. The interactions between irradiated cancer as well as 
irradiated or bystander and abscopal immune cells are manifold. 
These  radiation-induced interactions of immune cells in the 
tumor response are being elucidated for photonic radiation, but 
the effects of protons and carbon ions are largely unknown. First 
studies indicate a trend toward stronger cytokine expression by 
the tumor cells after carbon ion exposure. Extensive research 
is still necessary to unravel the mechanisms of the interplay of 
immune cells with the irradiated tumor in order to promote a more 
efficient therapy. The dependence on radiation quality, irradiation 
scheme as well as tumor origin makes a unifying statement about 
the expression of cytokines by tumor cells incredibly difficult. The 
ability of cytokines—as well as danger signals like HMGB1—to 
shift the immunoevasive tumor toward a state of damaged tissue 
engages the whole immune machinery to intervene against the 
neoplasia.
A cancer therapy approach using ionizing radiation and 
immune modulation has reached the clinical study status (76). 
Especially modulations that use agents promoting either acti-
vation or recruitment of immune cells are being considered. 
Postirradiation injection of non-irradiated endogenous immune 
cells, such as CTL, NK cells, and DC, to clear up the irradiated 
tumor more effectively are worth further investigation.
The use of radiation qualities that can more precisely target 
tumor cells, such as protons and carbon ions, in combination with 
immune therapy seems like a promising approach toward even 
more efficient cancer treatment, as the immune promoting effects 
of ionizing radiation can be supported by the local tumor control.
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